India's Drug Regulator Mandates Warning on Diabetes Drug Teneligliptin for Rare Skin Blisters

India's top drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has issued a crucial directive: manufacturers of the widely prescribed anti-diabetic drug Teneligliptin must now explicitly list 'Bullous Pemphigoid,' a serious blistering skin condition, as an adverse drug reaction. This move, finalized just days ago, aims to bolster patient safety for millions of Indians managing Type 2 Diabetes Mellitus and ensures drug companies update their product information immediately. The decision comes after thorough reviews by India's drug safety monitoring bodies, including the National Coordination Centre for the Pharmacovigilance Programme of India (NCC-PvPI) and an expert committee, which assessed real-world reports of adverse reactions to Teneligliptin. Bullous Pemphigoid is a rare but painful autoimmune condition causing large, fluid-filled blisters, and the CDSCO mandate highlights its proactive approach to post-market surveillance for drug safety, following a similar warning for common painkillers recently. Manufacturers across all States and Union Territories are now required to update their package insert and promotional literature to reflect this significant safety information. While patients are urged not to discontinue their Teneligliptin medication without first consulting their doctors, this directive empowers both healthcare professionals and individuals to be more vigilant about potential side effects, underscoring the ongoing push for greater transparency and patient awareness in drug administration.